Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 14:78:103786.
doi: 10.1016/j.amsu.2022.103786. eCollection 2022 Jun.

Immunohistochemical expression of transcription factors PAX5, OCT2, BCL6 and transcription regulator P53 in Non-Hodgkin lymphomas: A diagnostic cross-sectional study

Sawsan Ismail  1   2 , Yahya Elshimali  3   2 , Ali Daoud  1 , Zuheir Alshehabi  1   2
Affiliations

Immunohistochemical expression of transcription factors PAX5, OCT2, BCL6 and transcription regulator P53 in Non-Hodgkin lymphomas: A diagnostic cross-sectional study

Sawsan Ismail et al. Ann Med Surg (Lond). .

Abstract

Background: Non-Hodgkin lymphoma represents a heterogeneous group of tumors that constitute the seventh most common malignancy. Immunohistochemistry plays a major role in the detection of specific cell receptors. Transcription factors are a heterogeneous group of genes that play a critical role in the commitment, differentiation, and proliferation of specific cell types.

Methods: Paraffin-embedded tissue sections of non-Hodgkin lymphoma cases were selected, classified, and evaluated before staining with immunohistochemical markers (PAX5, OCT2, BCL6, and P53). Expression of the aforementioned markers was compared with histological subtypes and grades of lymphoma cases. Means of expression were also compared among histological subtypes.

Results: A total of 55 cases of NHL including 26 cases of low-grade lymphomas and 29 cases of high-grade lymphomas were included in the study. DLBCL and FL were the most common subtypes of high-grade and low-grade lymphomas respectively. Both PAX5 and OCT2 were positive in 44 cases of NHL (80%) including all cases of B-cell lymphomas. BCL6 and P53 demonstrated positive expression in 29.1% and 67.3% respectively. Interestingly, we found a significant association between the histological subtypes and the aforementioned markers (P-value<0.05).

Discussion: Expression of PAX5, OCT2, BCL, and P53 played a major role in the diagnosis and grading of non-Hodgkin lymphomas in our study. Both PAX5 and OCT2 provided more accuracy and specificity in the diagnosis of B-cell neoplasms compared to the classical B-cell markers. BCL6 expression reflected its role in germinal center formation in normal and malignant lymphoid tissues, and expression of P53 mirrored the accumulation of gene mutations in more aggressive lymphoma subtypes.

Conclusion: In this manuscript, we aimed to present a unique study that highlights the immunohistochemical expression of all the aforementioned factors among various histological subtypes of non-Hodgkin lymphomas with disparities in histological aggressiveness, highlighting a promising diagnostic and prognostic panel for non-Hodgkin lymphomas.

Keywords: Classification; Immunohistochemistry; Non-Hodgkin Lymphoma; Transcription factors; Transcription regulators.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Immunohistochemical expression of PAX5 in cases of NHL: (A,B,C: expression in DLBCL, D,E,F: expression in MZL, G,H,I: expression in FL, J,K,L: expression in B-LBL).
Fig. 2
Fig. 2
Immunohistochemical expression of OCT2 in cases of NHL: (A,B: expression in FL, C,D: expression in DLBCL, E,F: expression in MZL).
Fig. 3
Fig. 3
Immunohistochemical expression of BCL6 in cases of FL and DLBCL.
Fig. 4
Fig. 4
Immunohistochemical expression of P53.
Fig. 5
Fig. 5
Charts demonstrating positive and negative cases among diagnoses (A: PAX5 distribution among diagnoses, B: OCT2 distribution among diagnoses, C: BCL6 distribution among diagnoses, D: P53 distribution among diagnoses).
See this image and copyright information in PMC

References

    1. Swerdlow S.H., Campo E., Pileri S.A., et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi: 10.1182/blood-2016-01-643569. - DOI - PMC - PubMed
    1. Pratap S., Scordino T.S. Molecular and cellular genetics of non-Hodgkin lymphoma: diagnostic and prognostic implications. Exp. Mol. Pathol. 2019;106:44–51. doi: 10.1016/j.yexmp.2018.11.008. - DOI - PubMed
    1. Hester L.L., Park S.I., Wood W.A., et al. Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes. Cancer. 2019;125(7):1101–1112. doi: 10.1002/cncr.31821. - DOI - PMC - PubMed
    1. Said J.W. Aggressive B-cell lymphomas: how many categories do we need? Mod. Pathol. 2013;26(Suppl 1):S42–S56. doi: 10.1038/modpathol.2012.178. 0 1. - DOI - PMC - PubMed
    1. Cabanillas F., Rivera N., Pardo W.I. Indolent lymphomas that present with clinically aggressive features: a subset of low-grade lymphomas with a behavior inconsistent with the histologic diagnosis. Clin. Lymphoma, Myeloma & Leukemia. 2016;16(10):550–557. doi: 10.1016/j.clml.2016.08.011. - DOI - PubMed